MAPT and Alzheimer disease: Currently, the most predictive AD biomarker is the combination of lowered levels of amyloid-beta 42 (Aβ42) with increased total tau (tTau) and phosphorylated tau (pTau) levels in the cerebrospinal fluid (CSF).